Biosimilars Will Lift Sandoz Following Q2 Sales Slump
Reversal Of COVID-19 Impact Hurts Top Line
Having benefited financially from the increased demand from the coronavirus pandemic in the first quarter, Sandoz saw a reversal of fortune in Q2 as sales fell by more than one-tenth as reported, as the company explained to Generics Bulletin.
